Acrivon Therapeutics, Inc. Common Stock (ACRV) vs Atara Biotherapeutics, Inc. (ATRA)

A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and Atara Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Acrivon Therapeutics, Inc. Common Stock logo
ACRV
Acrivon Therapeutics, Inc. Common Stock
$83M
$1.94HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Atara Biotherapeutics, Inc. logo
ATRA
Atara Biotherapeutics, Inc.
$85M
$9.48HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

Total return — ACRV vs ATRA

growth of $100 · dividends reinvested · last 4y
ACRV -88.1% (-41.3%/yr)ATRA -92.2% (-47.1%/yr)ACRV compounded faster over this window
050100150Start $1002023202420252026$12$8
ACRV ATRA

ACRV vs ATRA: by the numbers

  • •ATRA is the larger company ($85M vs $83M market cap).
  • •Both run net losses; ACRV's is the smaller (0.00% vs -269.42% net margin).

Metrics side by side

Valuation

MetricACRVATRA
P/S ratioN/A13.79
P/B ratio0.96N/A

Profitability

MetricACRVATRA
Gross margin0.00%82.44%
Operating margin0.00%29.69%
Net margin0.00%-269.42%
ROE-85.65%N/A
ROIC-88.28%-100.35%

Growth (annualized)

MetricACRVATRA
Revenue CAGR (5Y)N/A56.10%
Total return CAGR (5Y)N/A-53.60%

Go deeper

Full ACRV analysisFull ATRA analysisInteractive comparison tool

Dig into the metrics

Acrivon Therapeutics, Inc. Common Stock ROEAtara Biotherapeutics ROEAcrivon Therapeutics, Inc. Common Stock operating marginAtara Biotherapeutics operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthAtara Biotherapeutics revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowAtara Biotherapeutics free cash flow

Acrivon Therapeutics, Inc. Common Stock & Atara Biotherapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.